Radnostix (INIS) files late 10-Q; Q1 sales $2.38M, expected loss $1.1M–$1.3M

Rhea-AI Filing Summary

Radnostix Inc. filed a Notification of Late Filing (Form 12b-25) stating it could not timely file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 because additional time is needed to complete valuation and accounting analyses of certain stock-based compensation awards, including restricted stock units. The company expects to file the Form 10-Q within the five-day extension period.

The filing discloses operating results for the three months ended March 31, 2026: Sales $2,378,924 versus $3,238,900 for the same period in 2025 (a decrease of approximately 27%). Radnostix expects a net loss of $1,100,000 to $1,300,000 for the quarter, versus a net loss of $112,694 in the prior-year period, attributing the change mainly to decreased sales after voluntary recalls and an operational shutdown for rehabilitation.

Insights

Accounting Analyst

Late filing driven by stock-based compensation valuation and pending accounting close.

Radnostix cites additional time needed to complete the valuation and related accounting analysis for certain stock-based compensation awards, including restricted stock units. Such valuations can affect expense timing and reported loss for the quarter when they change recognized compensation cost.

Watch for the finalized Form 10-Q to confirm the treatment and magnitude of any incremental stock‑based compensation expense and whether management revises previously disclosed estimates; timing is within the permitted five‑day extension.

Revenue/Operations Analyst

Reported sales decline of ~27% and a materially wider projected quarterly loss.

Sales fell to $2,378,924 from $3,238,900, driven by voluntary recalls in Theranostics, a shutdown for hot‑cell rehabilitation in Cobalt Products, and absence of prior-period catch‑up revenue for Calibration & Reference Products.

Operational recovery and resolution of recalls will determine near-term revenue trajectory; the company attributes an expected net loss range of $1.1M–$1.3M primarily to these sales disruptions.

Key Figures

Sales (Q1 2026): $2,378,924 Sales (Q1 2025): $3,238,900 Sales decline: 27% +2 more

5 metrics

Sales (Q1 2026) $2,378,924 three months ended March 31, 2026

Sales (Q1 2025) $3,238,900 three months ended March 31, 2025

Sales decline 27% Q1 2026 vs Q1 2025

Expected net loss (Q1 2026) $1,100,000–$1,300,000 three months ended March 31, 2026

Net loss (Q1 2025) $112,694 three months ended March 31, 2025

Key Terms

Form 12b-25, restricted stock units, hot cells

3 terms

Form 12b-25 regulatory

"Notification of Late Filing used to request a short extension"

Form 12b-25 is a notice a publicly traded company files with the U.S. Securities and Exchange Commission when it cannot deliver a required periodic report (like a quarterly or annual financial report) on time. It explains the reason for the delay and gives the company a short, temporary window to finish the report without being marked as delinquent; investors watch it because late filings can signal accounting, operational, or control issues that may affect a company’s reliability and stock risk, much like a missed homework deadline can raise concerns about a student’s preparedness.

restricted stock units financial

"valuation and related accounting analysis of certain stock-based compensation awards"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

hot cells technical

"rehabilitation of our process hot cells during the three months ended March 31, 2026"

Hot cells are heavily shielded, locked rooms equipped with remote-controlled tools used to handle, process and contain highly radioactive materials so people are not exposed. Think of them as a vault and robotic workbench combined for dangerous substances. For investors, hot cells signal substantial capital costs, strict regulatory oversight, ongoing safety and waste-management obligations, and potential revenue from services like medical isotope production or nuclear cleanup, all of which affect a company’s risk and cash needs.

			OMB APPROVAL
	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549		OMB Number:         3235-0058 Expires:         April 30, 2025 Estimated average burden hours per response         2.50
	FORM 12b-25		SEC FILE NUMBER
	NOTIFICATION OF LATE FILING		CUSIP NUMBER

(Check one):	☐ Form 10-K	☐ Form 20-F	☐ Form 11-K	☒ Form 10-Q	☐ Form 10-D	☐ Form N-CEN
	☐ Form N-CSR

For Period Ended: March 31, 2026

☐ Transition Report on Form 10-K

☐ Transition Report on Form 20-F

☐ Transition Report on Form 11-K

☐ Transition Report on Form 10-Q

For the Transition Period Ended:

Read Instruction (on back page) Before Preparing Form. Please Print or Type.

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

PART I — REGISTRANT INFORMATION

Radnostix Inc.

Full Name of Registrant

Former Name if Applicable

4137 Commerce Cir

Address of Principal Executive Office (Street and Number)

Idaho Falls, ID 83401

City, State and Zip Code

PART II — RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

	(a)	The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
☒	(b)	The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
	(c)	The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

Persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

PART III — NARRATIVE

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

Radnostix Inc. (the “Company”) was unable to complete its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 due to additional time needed to complete the valuation and related accounting analysis of certain stock-based compensation awards, including restricted stock units. The Company is working diligently to complete this analysis and expects to file the Form 10-Q within the five-day extension period.

PART IV — OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification

W. Matthew Cox		(208)		524-5300
(Name)		(Area Code)		(Telephone Number)

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).               Yes ☒ No ☐

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? Yes  ☒    No ☐

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

Sale of Product for the three months ended March 31, 2026 was $2,378,924 as compared to $3,238,900 for the same period in 2025, an overall decrease of $859,976, or approximately 27%. This decrease in sales was the result of lost sales in our Theranostics Products segment due to voluntary recalls of our Generic Sodium Iodide I131 on January 26, 2026, and of our Dibasic Sodium Phosphate Capsules on February 19, 2026, decreased sales in our Cobalt Products segment due to operational shutdown for the rehabilitation of our process hot cells during the three months ended March 31, 2026, and decreased sales in our Calibration & Reference Products because of catch-up revenue that occurred in the three months ended March 31, 2025 due to pent up demand from a global shortage of Cobalt-57 radioisotope that occurred during 2024 with no such catch-up revenue in the three months ended March 31, 2026.

We expect net loss will be between $1,100,000 and $1,300,000 for the three months ended March 31, 2026 compared to net loss of $112,694 for the same period in 2025. This increase in net loss of approximately $1,000,000 for the quarter was largely the result of decreased sales as discussed above.

Radnostix Inc

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date May 15, 2026 By /s/ W. Matthew Cox

INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative’s authority to sign on behalf of the registrant shall be filed with the form.

 ATTENTION 

Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).

GENERAL INSTRUCTIONS

1. This form is required by Rule 12b-25 (17 CFR 240.12b-25) of the General Rules and Regulations under the Securities Exchange Act of 1934.

2. One signed original and four conformed copies of this form and amendments thereto must be completed and filed with the Securities and Exchange Commission, Washington, D.C. 20549, in accordance with Rule 0-3 of the General Rules and Regulations under the Act. The information contained in or filed with the form will be made a matter of public record in the Commission files.

3. A manually signed copy of the form and amendments thereto shall be filed with each national securities exchange on which any class of securities of the registrant is registered.

4. Amendments to the notifications must also be filed on Form 12b-25 but need not restate information that has been correctly furnished. The form shall be clearly identified as an amended notification.

5. Interactive data submissions. This form shall not be used by electronic filers with respect to the submission or posting of an Interactive Data File (§232.11 of this chapter). Electronic filers unable to submit or post an Interactive Data File within the time period prescribed should comply with either Rule 201 or 202 of Regulation S-T (§232.201 and §232.202 of this chapter).

2

FAQ

Why did Radnostix (INIS) file a Form 12b-25 for the March 31, 2026 10-Q?

Radnostix filed the Form 12b-25 because it needs more time to complete valuation and accounting analyses of certain stock-based compensation awards including restricted stock units. The company states it will file the Form 10-Q within the five‑day extension period.

What were Radnostix's reported sales for Q1 2026 and how did they compare to Q1 2025?

Sales for the three months ended March 31, 2026 were $2,378,924, down from $3,238,900 in the same period of 2025. This represents a decrease of approximately 27%, per the filing, linked to recalls and operational shutdowns.

What net loss did Radnostix expect for the quarter ended March 31, 2026?

Radnostix expects a net loss between $1,100,000 and $1,300,000 for the three months ended March 31, 2026, compared with a net loss of $112,694 in the same 2025 period, attributing the increase largely to decreased sales.

What operational issues did Radnostix cite as reasons for lower sales in Q1 2026?

The company cited voluntary recalls of Generic Sodium Iodide I131 and Dibasic Sodium Phosphate Capsules, an operational shutdown for rehabilitation of process hot cells in its Cobalt Products segment, and lack of prior‑period catch‑up revenue.